סימפריקה 40 מג וטרינרי
zoetis israel holding b.v., israel - sarolaner - טבליות לעיסות - sarolaner 40 mg
סימפריקה 40 מג וטרינרי
zoetis israel holding b.v., israel - sarolaner - טבליות לעיסות - sarolaner 40 mg
סימפריקה 80 מג וטרינרי
zoetis israel holding b.v., israel - sarolaner - טבליות לעיסות - sarolaner 80 mg
סימפריקה 80 מג וטרינרי
zoetis israel holding b.v., israel - sarolaner - טבליות לעיסות - sarolaner 80 mg
סימפריקה 5 מג וטרינרי
zoetis israel holding b.v., israel - sarolaner - טבליות לעיסות - sarolaner 5 mg
טרקליר 62.5 מג
j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 62.5 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease
טרקליר 125 מג
j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 125 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease
קרינון % 8
merck serono ltd - progesterone - ג'ל - progesterone 8 %w/w - progesterone - progesterone - treatment of infertility due to inadequete luteal phase. for use during in-vitro fertilisation, where infertility is mainly due to tubal idiopathic or endometriosis linked sterility associated with normal obulatory.
קם-רהו די i.m
kamada ltd, israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - pregnancy/other obstetric conditions, suppression of rh immunization in non-sensitized rh0 (d) negative women delivering an rh0 positive baby or when the baby's rh type is unknown. suppression of rh immunization after spontaneous or induced abortions threatened abortion associated with maternal bleeding amniocentesis chorionic villus sampling ruptured tubal pregnancy and significant abdominal trauma. kam rh0 -d im should be given within 72 hours of the event. it may be given even after up to one month although efficacy may be somewhat reduced.transfusion: suppression of rh isoimmunization in rh0 (d) antigen-negative patients transfused with rh0 (d) antigen-positive rbcs of blood components containing rh0 (d) antigen-positive rbcs . initate treatment within 72 hours of exposure.